These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24909571)

  • 41. Type O blood group associates with higher anti-JC polyomavirus antibody levels.
    Frenken P; Hartung HP; Olsson T; Adams O; Warnke C
    Brain Behav; 2021 Aug; 11(8):e2298. PubMed ID: 34291599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Generation of JC Polyoma Pseudovirus for High-Throughput Measurement of Neutralizing Antibodies.
    Matsuda M; Li TC; Nakanishi A; Nakamichi K; Saito M; Suzuki T; Matsuura T; Muramatsu M; Suzuki T; Miura Y; Suzuki R
    Diagnostics (Basel); 2024 Jan; 14(3):. PubMed ID: 38337826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natalizumab: risk stratification of individual patients with multiple sclerosis.
    Tur C; Montalban X
    CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility?
    Jelcic I; Combaluzier B; Jelcic I; Sospedra M; Grimm J; Martin R
    Swiss Med Wkly; 2017; 147():w14520. PubMed ID: 29120025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH; Moraes L; Fink MC; Callegaro D; Romano CM; Oliveira AC
    Arq Neuropsiquiatr; 2014 Dec; 72(12):960-5. PubMed ID: 25465776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
    Takao M
    Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients.
    Rossi F; Li X; Jacobson L; Levine AJ; Chen Y; Palella FJ; Margolick J; Viscidi R
    Virology; 2015 Nov; 485():467-72. PubMed ID: 26356797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding polyomavirus CNS disease - a perspective from mouse models.
    Ayers KN; Carey SN; Lukacher AE
    FEBS J; 2022 Oct; 289(19):5744-5761. PubMed ID: 34145975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D; Giovannoni G
    Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
    Schwab N; Schneider-Hohendorf T; Posevitz V; Breuer J; Göbel K; Windhagen S; Brochet B; Vermersch P; Lebrun-Frenay C; Posevitz-Fejfár A; Capra R; Imberti L; Straeten V; Haas J; Wildemann B; Havla J; Kümpfel T; Meinl I; Niessen K; Goelz S; Kleinschnitz C; Warnke C; Buck D; Gold R; Kieseier BC; Meuth SG; Foley J; Chan A; Brassat D; Wiendl H
    Neurology; 2013 Sep; 81(10):865-71. PubMed ID: 23925765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.
    Giovannelli I; Martelli F; Repice A; Massacesi L; Azzi A; Giannecchini S
    J Neurovirol; 2015 Dec; 21(6):666-70. PubMed ID: 25678142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Berger JR; Houff SA; Major EO
    MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.
    Lin J; Bettin P; Lee JK; Ho JK; Sadiq SA
    J Neuroimmunol; 2013 Aug; 261(1-2):123-8. PubMed ID: 23800458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.